Bristol-Myers Squibb (BMY) Could Be Worth $59-$75 In Takeout W/O CM-227 – GoldmanArticleGoldman Sachs maintained a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY) with a price target of $63.00.Analyst Jami Rubin says the stock could be worth $64-$74 per share depending on the varying degrees of success of CM-227. The analyst also notes that in a takeout scenario the stock could be worth $59-$75 per share with no value for CM-277.
Bristol-Myers Squibb (BMY) Could Be Worth $59-$75 In Takeout W/O CM-227 – GoldmanArticleGoldman Sachs maintained a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY) with a price target of $63.00.Analyst Jami Rubin says the stock could be worth $64-$74 per share depending on the varying degrees of success of CM-227. The analyst also notes that in a takeout scenario the stock could be worth $59-$75 per share with no value for CM-277.Source: Bristol-Myers Squibb (BMY) Could Be Worth $59-$75 In Takeout W/O CM-227 – Goldman
We believe CM-227 works so what is the price then?